UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of the
Securities and Exchange Act of 1934
Date of Report (Date of earliest reported event): December 3, 2004
GEOPHARMA, INC.
(Exact name of registrant as specified in charter)
| | | | |
| Florida | | 001-16185 | | 59-2600232 |
(State or other jurisdiction of incorporation) | | (Commission File Number) | | (IRS Employer Identification No.) |
| | |
| 6950 Bryan Dairy Road, Largo, Florida | | 33777 |
| (Address of principal executive offices) | | (Zip Code) |
Registrant’s telephone number, including area code: (727) 544-8866
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
ITEM 5.02 Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers
On December 3, 2004, Joseph Zappala submitted his resignation to GeoPharma, Inc., a Florida corporation (the “Company”), resigning as a member of the Company’s Board of Directors, effective immediately. A copy of Mr. Zappala’s resignation is attached hereto as an exhibit.
The Company provided a copy of this Form 8-K to Mr. Zappala today, December 6, 2004, and his response to the disclosure is also attached as an exhibit.
ITEM 9.01. Financial Statements and Exhibits.
99.1 Letter of Resignation from Joseph Zappala, dated December 3, 2004
99.2 Letter from Mr. Zappala agreeing with disclosure, dated December 6, 2004
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| | |
| | | GEOPHARMA, INC. |
| |
Date: December 6, 2004 | | /s/ Mihir K. Taneja
|
| | | Mihir K. Taneja, |
| | | Chief Executive Officer |
| |
| | | /s/ Carol Dore-Falcone
|
| | | Carol Dore-Falcone, Vice President and Chief Financial Officer |
